Kinetics of 2 different high-sensitive troponins during targeted temperature management in out-of-hospital cardiac arrest patients with acute myocardial infarction: a post hoc sub-study of a randomised clinical trial

Alf Inge Larsen1,2*, Anders Morten Grejs3,4, Simon Tilma Vistisen3,4, Kristian Strand9, Øyvind Skadberg6, Anni Nørgaard Jeppesen8, Christophe H. V. Duez3,7, Hans Kirkegaard3,7 and Eldar Søreide2,5

Abstract

Introduction: Short term hypothermia has been suggested to have cardio protective properties in acute myocardial infarction (AMI) by reducing infarct size as assessed by troponins. There are limited data on the kinetics of these biomarkers in comatose out-of-hospital cardiac arrest (OHCA) patients, with and without AMI, undergoing targeted temperature management (TTM) in the ICU.

Purpose: The aim of this post hoc analyses was to evaluate and compare the kinetics of two high-sensitivity cardiac troponins in OHCA survivors, with and without acute myocardial infarction (AMI), during TTM of different durations [24 h (standard) vs. 48 h (prolonged)].

Methods: In a sub-cohort (n = 114) of the international, multicentre, randomized controlled study “TTH48” we measured high-sensitive troponin T (hs-cTnT), high-sensitive troponin I (hs-cTnI) and CK-MB at the following time points: Arrival, 24 h, 48 h and 72 h from reaching the target temperature range of 33 ± 1 °C. All patients diagnosed with an AMI at the immediate coronary angiogram (CAG)—18 in the 24-h group and 25 in the 48-h group—underwent PCI with stent implantation. There were no stent thromboses.

Results: Both the hs-cTnT and hs-cTnI changes over time were highly influenced by the cause of OHCA (AMI vs. non-AMI). In contrast to non-AMI patients, both troponins remained elevated at 72 h in AMI patients. There was no difference between the two time-differentiated TTM groups in the kinetics for the two troponins.

Conclusion: In comatose OHCA survivors with an aetiology of AMI levels of both hs-cTnI and hs-cTnT remained elevated for 72 h, which is in contrast to the well-described kinetic profile of troponins in normotherm AMI patients. There was no difference in kinetic profile between the two high sensitive assays. Different duration of TTM did not influence the kinetics of the troponins.

*Correspondence: laai@sus.no; alfil@broadpark.no
1 Department of Cardiology, Stavanger University Hospital, Stavanger, Norway
Full list of author information is available at the end of the article.
Introduction
Rise and fall of troponin levels following a period of ischemia provide important information about diagnosis of acute myocardial infarction (AMI) and infarct size [1, 2]. Elevated troponins are also observed in patients with out-of-hospital cardiac arrest (OHCA) without myocardial infarction. However, this elevation is modest and normalizes early [3] and the kinetic profile in this subset of patients with OHCA is supposed to be distinct from that after AMI [4].

Although mild hypothermia, now referred to as targeted temperature management (TTM) at 33–36 °C, for 24 h in comatose survivors after OHCA has become standard of care to limit the anoxic brain injury [5, 6], the kinetics of high-sensitive troponins and the effect of TTM on a potentially underlying AMI in this setting has not been extensively evaluated [7]. Experimental studies have shown that TTM induced before reperfusion of the acute coronary occlusion may reduce myocardial infarct size [8, 9]. A pilot study also indicated that patients with large ST segment elevation myocardial infarction (STEMI) benefit from short-term hypothermia induced before PCI with a subsequent reduction of infarct size [10]. Cautious interpretation of sub-group analyses in a recent study may indicate a favourable outcome with the use of TTM [11]. Moreover, in the Chill AMI trial there was a lower incidence of heart failure and a possible effect in patients with early anterior ST-segment elevation myocardial infarctions [12].

The aim of the present study was to explore and compare the kinetic pattern of two high-sensitivity troponins; hs-cTnT and hs-cTnI, in OHCA patients, with and without AMI, undergoing TTM at 33 ± 1 °C of two different durations in the intensive care unit (ICU).

Methods
This study was a pre-specified explorative sub-study of the”Targeted Temperature Management for 48 vs 24 Hours and Neurological Outcome After Out-of-Hospital Cardiac Arrest: A Randomized Clinical Trial” (TTH48) in comatose OHCA survivors enrolled at 2 specific centres from February 2013 to June 2016 (ClinicalTrials.gov Identifier: NCT01689077) [13]. In brief, the TTH48 trial was an investigator-initiated, blinded-outcome-assessor, parallel, multicenter, randomized clinical trial, which evaluated effects of prolonged TTM for 48 h compared to standard 24-h TTM at 33 ± 1 °C. Inclusion criteria were OHCA with a presumed cardiac origin, sustained return of spontaneous circulation (ROSC), Glasgow Coma Score less than 8 and age older than 17 years and below 80 years. The full protocol has been described previously [14].

![Fig. 1 Kinetics of TnI, TnT and CK-mb in comatose survivors after OHCA. AMI compared to non-AMI. Pooled analyses of both treatment arms 24 and 48 h of TTM. Patients stratified by acute myocardial infarction (AMI) or non-AMI. hs-cTnT, hs-cTnI, CK-MB is log transformed, (mean ± SE). The units are ng/l. TNT; high sensitive troponin T, TNI; high sensitive troponin I, CK-MB; Creatine kinase MB, OHCA; out of hospital cardiac arrest, TTM; target temperature management.](image-url)
**Acute myocardial infarction**
AMI was defined as thrombotic lesion identified at the immediate coronary angiography (CAG) necessitating a percutaneous coronary intervention (PCI).

**TTM**
 Patients were randomized to TTM maintained for either 24 or 48 h at 33±1 °C (Fig. 1). After screening for eligibility, patients were randomly assigned in a 1:1 ratio to 1 of the 2 study groups, using a web-based central randomization procedure provided by the Department of Clinical Medicine, Aarhus University, Denmark. Both surface and invasive cooling methods with feedback were allowed. Cooling was initiated at admission to the ICU or at the cardiac catheterization laboratory. The patients were cooled as fast as possible to a target temperature of 33±1 °C, and rewarming was conducted at a maximum rate of 0.5 °C/h until a core temperature of 37°C was reached.

**Clinical data collection**
We collected study population characteristics such as gender, age, body mass index, previous medical history along with pre-hospital data following the Utstein template. Furthermore, we collected in-hospital data from the records in the cardiac catheterization laboratories and from the ICUs.

**Blood sampling and analyses**
We collected blood samples for analyses at arrival, after 24 h, 48 h and 72 h. The Elecsys 2010 hs-Troponin T immunoassay (Roche Diagnostics, Penzberg, Germany) was used for measuring the hs-cTnT concentrations (cut-off point for the diagnosis of AMI: 14 ng/L [99th percentile of the upper reference limit (URL)]), while Troponin I was analysed using a commercially available high-sensitive cTnl STAT assay from Abbott Diagnostics, Architekt i2000SR (Abbott Diagnostics, Illinios, USA) (immunochemistry) with a lower limit of detection of 1.6 ng/l assay for measuring hs-cTnl concentration (cut-off point: 15 ng/L for women and 30 for men [99th percentile of the upper reference limit (URL)]). Additionally, the measurements of CK-MB were carried out as a supplemental option for detecting myocardial injury and diagnosing myocardial infarction. The ARCHITECT STAT CK-MB immunoassay (Abbott Laboratories, Lake Bluff, Ill.) was applied for the measurement of the CK-MB concentrations. (cut-off points: 4.0 mg/L URL for women and 7.0 mg/L URL for men). We also measured and analysed serum creatinine at admission, after 24 h, 48 h and 72 h.

**Statistics**
Data were managed using Research Electronic Data Capture; REDCap [15, 16]. Baseline characteristics were compared between treatment groups with Wilcoxon rank-sum test, or chi square test.

The influence of time ("pharmacokinetics") and treatment group assignment (TTM duration) on hs-cTnT and hs-cTnl levels were addressed with linear mixed effects model analyses also taking into account the cause of cardiac arrest (AMI or non-AMI) as well as the serum creatinine level, because it is believed that renal filtration is responsible for clearance of TnT and TnI. A linear mixed effects model was applied to answer whether serum creatinine level was affected by treatment group assignment and how the serum-concentration changed over time. All statistical analyses were done using R (Version 3.5.1 using Rstudio version 1.1.453) with the tableone, nlme and lme4 packages installed. p < 0.05 was considered statistically significant.

**Results**
One hundred and fourteen patients were included in 2 cardiac arrest centers (Aarhus DK and Stavanger NO) between February 2013 and June 2016. Patients diagnosed with AMI (n=43) had an angiographically documented thrombotic lesion, and all of these patients underwent subsequent PCI (18 in the 24-h group and 25 in the 48-h group). At baseline, there were no differences in biochemistry or demographics of AMI versus non-AMI patients except for S-creatinine levels, which was statistically significantly lower in the patients with AMI as aetiology compared to patients with no AMI. Additionally there was a borderline difference in prevalence of diabetes (Table 1). There were no stent thromboses.

The presence of AMI highly altered the general level and kinetics of both troponins (Fig. 1). In this group specifically, there was no statistically significant difference in the kinetic pattern of the 2 troponins between the two time-differentiated TTM groups (Fig. 2). However, both hs-cTnT and hs-cTnl remained elevated at 72 h in both TTM groups with AMI. This is different from the well-known kinetic profile in normothermic patients with AMI in whom both troponins are almost halved at 50 h despite the double dome curve of TNT.

Level of serum creatinine were, at each time point, statistically significantly lower in the patients with AMI as aetiology compared to patients with no AMI (Fig. 3). Level of serum creatinine highly altered the general level of both troponins. Although affecting the general...
troponin level, serum creatinine was not in itself affected by the treatment group.

Different duration of TTM did not influence the kinetics of the troponins (Fig. 4).

Female gender and age > 63 was associated with higher levels of troponins (Fig. 5). However, a higher number of patients with AMI as an aetiology mainly drove the effect of age for OHCA in the elderly. Figure 6 is highlighting the summary of the study.

**Discussion**

The main finding in the current study was that both levels of hs-cTnT and hs-cTnI remained elevated at time point 72 h in OHCA patients diagnosed with AMI undergoing TTM. This contrasts the well-known kinetic profile of troponins in patients with AMI not undergoing TTM [17]. There was no difference in kinetics between the two troponins.

Further, we found that serum level of creatinine was a major predictor for alterations of the kinetics of both troponins. Finally, we found that the kinetic profiles of hs-cTnT and hs-cTnI were not affected by length of TTM (24 h and 48 h of TTM at 33 °C).

**Comparison with previous studies**

The typical double doom kinetic curve of hs-cTnT in normothermic patients following AMI is caused by the early release from a ‘cytosolic pool’ contributing to an initial peak with a second peak, which also reflects infarct size, caused by degradation of the contractile apparatus (‘structural pool’). In contrast to this, hs-cTnI profile is monophasic, lacking a second, late peak. However, both troponins are falling after 24–48 h in STEMI patients treated with primary PCI.

In the current study levels of both troponins remained elevated at 72 h. These findings of persistent elevated levels of troponins during TTM in patients with AMI, indicating additional myocardial injury, are in contrast to a pooled analysis of six randomized trials which indicated a reduction in infarct size in anterior STEMI patients who were cooled to < 35 °C at the time of reperfusion, assessed by either single-photon emission computed tomography (SPECT) or cardiac magnetic resonance imaging (CMR) [18]. However, a recently published report concluded that out-of-hospital induced cooling, as an adjunct to primary percutaneous coronary intervention did not improve myocardial salvage as assessed with CMR in patients with STEMI [19]. Additionally, in the Cool-AMI study, a reduction of body core temperature to 33.3 °C before primary PCI in patients with anterior STEMI was associated with increased risk for adverse events [20]. Concomitant reduced fall in levels of CK-MB in the 48 h treatment arm compared with the 24-h arm in a sub-study of the TTH 48 trial further support the potential deleterious effects on the myocardium of TTM for comatose survivors of OHCA in patients with AMI [21].

### Table 1 Baseline demographics and admission lab values in patients with Non-AMI and AMI

| Stratified by group | Non-AMI | AMI | p   |
|-------------------|---------|-----|-----|
| n                 | 71      | 43  |     |
| Age (years)       | 61 [53,68] | 65 [55,70] | 0.166 |
| Male gender (%)   | 60 (84.5) | 38 (88.4) | 0.766 |
| BMI (kg/m²)       | 27 [24,29] | 28 [25,29] | 0.382 |
| Diabetes mellitus (%) | 18 (25.4) | 4 (9.3) | 0.063 |
| Smoking (%)       | 32 (22.0) | 8 (20.5) | 0.862 |
| Never             | 21 (35.6) | 16 (41.0) |     |
| Present           | 25 (42.4) | 15 (38.5) |     |
| Hypercholesterolemia (%) | 35 (49.3) | 20 (46.5) | 0.924 |
| Primary rhythm (%)| 16 (22.5) | 9 (20.9) |     |
| Alcohol abuse (%) | 31 (20) | 9 (20) |     |
| CPR performed (%) | 61 (85.9) | 39 (90.7) | 0.646 |
| No flow time (minutes) | 1 [0,1] | 0 [0,1] | 0.49 |
| Low flow time (minutes) | 17 [12,28] | 21 [15,27] | 0.361 |
| ROSC to CAG (minutes) | 20 [13,28] | 22 [16,27] | 0.438 |
| ROSC (%)          | 7 (9.9) | 3 (7.0) | 0.877 |
| Non-shockable (%) | 9 (12.7) | 3 (7.0) |     |
| Shockable (%)     | 55 (77.5) | 37 (86.0) |     |
| No flow time (minutes) | 1 [0,1] | 0 [0,1] | 0.49 |
| Low flow time (minutes) | 17 [12,28] | 21 [15,27] | 0.361 |
| ROSC to CAG (minutes) | 20 [13,28] | 22 [16,27] | 0.438 |
| LUCAS (%)         | 0 (0.0) | 1 (2.3) | 0.187 |
| CKMB (ug/l)       | 7 [4,13] | 8 [5,22] | 0.085 |
| Lactate (mmol/l)  | 3 [2,7] | 3 [2,5] | 0.617 |
| Creatinine (mmol/l) | 105 [88,125] | 91 [82,108] | 0.012 |
| SAPSII            | 52 [47,59] | 50 [44,58] | 0.537 |
| Surface cooling (%) | 20 (28.2) | 14 (32.6) | 0.775 |

**CPR** cardiopulmonary resuscitation, **ROSC** return of spontaneous circulation, **CAG** coronary angiography, **AMI** acute myocardial infarction. Continuous variables are reported as median [interquartile range].
Renal function and troponin levels
In addition to the obvious typical rise and fall due to AMI, troponin values have also been shown to rise and fall with increasing and decreasing kidney function, suggesting renal clearance as a contributing factor of the rise and fall independence of myocardial injury [22]. In Chronic Renal Failure (CRF) patients, hs-cTnT increases over time as renal function decreases. Each 15 mL/min/1.73 m² lower mean estimated glomerular filtration rate (GFR) has been shown to be associated with a 23% higher baseline hs-cTnT and 9% steeper increase in hs-cTnT in stable Chronic renal disease (CRD) stage 4–5 patients [23]. In the current study, level of serum creatinine per se also had a significant impact on troponin levels. However, admission serum creatinine was lower in the AMI group indicating that the observed persistent elevated levels of troponins in this group are unlikely to be related to kidney function only.

Hypothermia and renal function
Acute kidney injury (AKI) is common in OHCA, depending on definition and patient selection [24, 25].

Fig. 2 Kinetics of TnI, TnT and CK-mb in comatose survivors after OHCA treated with TTM in the TTH48 trial stratified by cause of event (AMI vs. non-AMI) and treatment group (TTM 24 h vs. TTM 48 h). Patients stratified by AMI and length of TTM, (mean ± SE). hs-cTnT, hs-cTnI, CK-MB. The units are ng/l. TnI; high sensitive troponin I, TnT; high sensitive troponin T, CK-MB, Creatin kinase MB, OHCA; out of hospital cardiac arrest, TTM; target temperature management.

Fig. 3 Changes in serum creatinine during 72 h as a function of aetiology (AMI or not AMI), treatment group (TTM 24 h vs. TTM 48 h) and the combination of these. Patients stratified by AMI or no-AMI, (mean ± SE). sCr; serum creatinine, AMI; acute myocardial infarction, TTM; target temperature management.
The post cardiac arrest syndrome is characterised by multi-organ dysfunction as a result of an acute inflammatory response and persistent haemodynamic instability aggravated by ischaemia–reperfusion injury and on-going shock aggravating renal injury [26]. It is suggested that TTM impacts the development of AKI as indicated in a sub-study of the Hypothermia after Cardiac Arrest Study, in which hypothermia to 33 °C was associated with a reduced calculated glomerular filtration rate [27]. However, the evidences are diverging, and mild therapeutic hypothermia does not seem to be reno-protective [28]. Serum creatinine rose in both groups, but there were no differences between treatment groups indicating any additional drop in renal function in the 48-h group.
Contrast induced nephropathy

It has been speculated that the sustained levels of troponins may be explained by an additional aggravation of renal failure due to early coronary angiography (CAG) and PCI in OHCA survivors with AMI. Yet, in a sub-study of the TTH48 trial on AKI there was no association between prolonged TTM at 33 °C and risk of AKI during the first seven days of admission [29]. Moreover, recent studies show that early CAG-PCI does not increase the risk of AKI per se. In the COACT trial, the
incidence of AKI and need for renal-replacement therapy did not differ between early versus late CAG-PCI [30]. Furthermore, in the post hoc analysis of the targeted temperature management (TTM) trial, early CAG-PCI was even associated with less AKI [31].

There is thus no clear evidence of an acute negative effect of CAG on renal function in TTM explaining the sustained elevated levels of troponins in the subset of patients with AMI undergoing CAG and PCI. This finding is also supporting the hypothesis of increased myocardial injury as a source for sustained elevation of troponins also in patients with CRF. There is emerging evidence that increases in cTnT in patients without clinical symptoms of AMI with end stage renal disease indicates subclinical myocardial necrosis or injury [32, 33]. This is partly based on the findings of no difference between patients with normal renal function or end stage renal disease (ESRD) in the elimination half-life and apparent half-life of serum cTnI during myocardial necrosis [34]. The intact troponin molecule is large, and it is unlikely that the kidneys are primarily responsible for clearance from serum. However, work by Diris et al. suggests that the troponin molecule is degraded into smaller fragments, which can be detected by the assays and are small enough to be filtered by the kidneys. This mechanism may contribute to the elevation of troponin in severe renal failure [35].

The mechanisms for the sustained troponin plateau phase in the present AMI patients undergoing TTM may thus be plural. Reduced renal clearance is suggested to contribute to the sustained levels of troponins in some patients. However, we found no association between prolonged TTM at 33 °C and the risk of AKI. Therefore, increased myocardial necrosis cannot be excluded. This may be reinforced by too low target mean arterial pressure increasing troponin levels as shown in a study on 120 OHCA patients with AMI and shock [36]. Additionally, levels of Hs-TnI and Hs-TnT have been shown to be a marker of poor prognosis after OHCA [37].

Both cTnI and cTnT are released from necrotic myocardium as intact proteins and as degradation products [38]. Whether the substantial biochemical differences between cTnI and cTnT including molecular weight between cTnI (23 kDa) and cTnT (35 kDa) could result in different diagnostic and prognostic performances for both biomarkers are not well explored [39]. In the current study this difference in pharmacokinetics was not evident. This may be due to the myo-fibrillar injury and mitochondrial oedema and reversible ultrastructural findings in medically and experimentally induced moderate or deep hypothermic blood cardioplegia [40, 41].

Finally, sustained release of troponins might be caused by stent thrombosis. However, there were no clinical indication of acute stent thrombosis. This is also in accordance with a recent study showing that the incidence of stent thrombosis was low in OHCA survivors undergoing state of the art PCI [42]. On the other hand, although the confirmation of a diagnosis of stent thrombosis using troponin dynamics will be challenging, one would expect a new substantial peak in troponin levels and signs of acute ischemia in the ECG.

The findings of remained elevated troponins in comatose OHCA survivors undergoing TTM might indicate a potential risk for cooling induced myocardial damage which is associated with multi-organ failure. Recently the TTM2 trial showed that targeted hypothermia did not lead to a lower incidence of death by 6 months than targeted normothermia in patients with coma after out-of-hospital cardiac arrest [43]. The results were broadly consistent with the results of the previous TTM trial. The combined results of the two trials imply a low likelihood of any meaningful clinical improvement with hypothermia as compared with normothermia, since 36 °C may be considered to be the lower boundary of normothermia. In the TTM2 trial arrhythmias causing hemodynamic compromise were more common in the hypothermia group than in the normothermia group. Possible reasons for this include electrolyte disturbances, fluid status, and a temperature effect on cardiac myocytes [44].

Strengths and limitations
This study had a prospective design with pre-set time-points for analyses of troponins. It was performed in two cardiac arrest centres with well-developed systems for all post cardiac arrest patients. On the other hand, there was a relative low number of patients included and a limited number of time points to obtain a more precise kinetic profile.

Conclusions
In OHCA survivors we found no difference in the pharmacokinetics of two high-sensitive troponins during TTM at 33 °C for 24 or 48 h. Both troponins remained elevated at 72 h in the patients undergoing PCI for AMI unlike the kinetic profile for these troponins in normothermic patients with AMI. The usefulness of hs-troponin I and T might thus not be appropriate for diagnosing new coronary events in these patients.

Abbreviations
AKI: Acute kidney injury; AMI: Acute myocardial infarction; CAG: Coronary angiography; CRF: Chronic Renal Failure; CK-MB: Creatine kinase MB; CMR: Cardiac magnetic resonance imaging; CKD: Chronic renal disease; ESRD: End stage renal disease; GFR: Glomerular filtration rate; hs-cTnI: High-sensitivity troponin I; hs-cTnT: High-sensitivity troponin T; ICU: Intensive care unit; OHCA: Out-of-hospital cardiac arrest; PCI: Percutaneous coronary intervention; REDCap: Research Electronic Data Capture; ROSC: Return of spontaneous circulation;
SPECT: Single-photon emission computed tomography; STEMI: ST segment elevation myocardial infarction; TTM: Targeted temperature management; URL: Upper reference limit.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12872-022-02778-4.

Additional file 1. Raw Data Set.

Acknowledgements

The authors thank Anne Larsen, Wenche Mathiesen, Aase Reinertsen and Simon Granum for their contribution to data collection.

Author contributions

All ES, HK, KG and AHG designed the study and wrote the manuscript. SV performed the statistics and created the figures. ANI and CD included patients and participated in the manuscript phase. All authors reviewed and approved the manuscript.

Funding

Open access funding provided by University of Bergen. Aarhus University Hospital, Aalborg University Hospital, Stavanger University Hospital, The Danish Society of Anaesthesiology and Intensive Care Medicine, The Scandinavian Society of Anaesthesiology and Intensive Care Medicine, Foundation of 1870 and the Aase and Ejnar Danielsen Foundation financially supported this study. The sponsors had no influence on the analysis, the manuscript, or the choice of publishing journal. None of the contributors are from the pharmaceutical industry.

Availability of data and materials

All data are available in PDF format in “Additional file 1”.

Declarations

Ethical approval and consent to participate

The ethics committee in both the participating centers approved the study protocol. The study was conducted according to the requirements of the Declaration of Helsinki; written informed consent was obtained from the next of kin or a legal surrogate before randomization, and from each patient who regained mental capacity, according to local ethical approval. All methods were carried out in accordance with relevant guidelines and regulations. All experimental protocols were approved by The Ethics Committee of Central Denmark Region on 2 January 2011 (journal number 20110022). The Regional Ethics Committee of Western Norway on 9 October 2013 (ref 2013/1486).

Consent for publication

Not applicable.

Competing interests

Anders Grejs reports to have received speaker fees from Novartis and MSD. All other authors declare no conflict of interest. Authorship: All authors had

References

1. Gaze DC, Collinson PO. Multiple molecular forms of circulating cardiac troponin: analytical and clinical significance. Ann Clin Biochem. 2008;45:349–55.
2. Hallén J. Troponin for the estimation of infarct size: What have we learned? Cardiology. 2012;121:204–12.
3. Sang Hoon O, Kim YM, Kim HI, Youn CS, Choi SP, Wee JH, Kim SH, Jeong WJ, Park KN. Implication of Cardiac marker elevation in patients who resuscitated from out-of-hospital cardiac arrest. Am J Emerg Med. 2012;30(3):464–71. https://doi.org/10.1016/j.ajem.2010.12.022.
4. Lin CC, Chiu TF, Fang JY, Kuan JT, Chen JC. The influence of cardiopulmonary resuscitation without defibrillation on serum levels of cardiac enzymes: a time course study of out-of-hospital cardiac arrest survivors. Resuscitation. 2006;68:343–9.
5. The Hypothermia after Cardiac Arrest (HACA) Study Group. Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. N Engl J Med. 2002;346:54–9.
6. Lascamou JB, Merdji H, Le Gouge A, CRICS-TRIGGERSEP Group, et al. Targeted temperature management for cardiac arrest with nonshockable rhythm. N Engl J Med. 2019;381:2327–37.
7. Callaway CW, Donnino MW, Fink EL, et al. Part 8: post-cardiac arrest care. 2015 American heart association guidelines update for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2015;132(23 suppl 2):S56–82.
8. Göttberg M, Olivcrona GK, Engblom H, et al. Rapid short-duration hypothermia with cold saline and endovascular cooling before reperfusion reduces microvascular obstruction and myocardial infarct size. BMC Cardiovasc Disord. 2008;8:7.
9. Dae MW, Gao DW, Sessler DI, Chair K, Stillson CA. Effect of endovascular cooling on myocardial temperature, infarct size, and cardiac output in human-sized pigs. Am J Physiol Heart Circ Physiol. 2002;282:H1584–91.
10. Göttberg M, Olivcrona GK, Engblom H, et al. A pilot study of rapid cooling by cold saline and endovascular cooling before reperfusion in patients with ST-elevation myocardial infarction. Circ Cardiovasc Interv. 2010;3:400–7.
11. Koreny M, Sterz F, Uray T, et al. Effect of cooling after human cardiac arrest on myocardial infarct size. Resuscitation. 2009;80:56–60.
12. Erlinge D, Göttberg M, Lang J, Holzer M, Noc M, Clemmensen P, Jensen U, Metzler B, James S, Böcker HE, Omerovic E, Engblom H, Carlsson M, Arheden H, Östlund O, Wallentin L, Harnek J, Olivcrona GK. Rapid endo-
vascular catheter core cooling combined with cold saline as an adjunct to percutaneous coronary intervention for the treatment of acute myo-
cardial infarction. J Am Coll Cardiol. 2014;63(18):1857–65. https://doi.org/10.1016/j.jacc.2013.12.027.
13. Kirkegaard H, Sareide E, de Haas J, et al. Targeted temperature management for 48 vs 24 hours and neurologic outcome after out-of-hospital cardiac arrest: a randomized clinical trial. JAMA. 2017;318:341–50.
14. Kirkegaard H, Rasmussen BS, de Haas J, et al. Time-differentiated target temperature management after out-of-hospital cardiac arrest: a multicentre, randomised, parallel-group, assessor-blinded clinical trial (the TTH48 trial): study protocol for a randomised controlled trial. Trials. 2016;17:228.
15. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap) – a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377–81.
16. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O’Neal L, et al. REDCap consortium, the REDCap consortium: building an international community of software partners. J Biomed Inform. 2019;95:103208.
17. Laugaudin G, Kuster N, Petion A, et al. Kinetics of high-sensitivity cardiac troponin T and I differ in patients with ST-segment elevation myocardial infarction treated by primary coronary intervention. Eur Heart J Acute Cardiovasc Care. 2016;5:354–63.
18. Dae M, O’Neill W, Grines C, et al. Effects of endovascular cooling on infarct size in ST-segment elevation myocardial infarction: a patient-level pooled analysis from randomized trials. J Inter V Cardiol. 2018;31:269–76.
19. Testori C, Beitzke D, Mangold A, Sterz F, Loewe C, Weiser C. Out-of-hospital initiation of hypothermia in ST-segment elevation myocardial infarction: a randomised trial. Heart. 2019;105:531–7.

20. Noc M, Laarman P, Neskorv, AN, et al. A multicentre, prospective, randomised controlled trial to assess the safety and effectiveness of cooling as an adjunctive therapy to percutaneous intervention in patients with acute myocardial infarction: the COOL AMI EU pivotal trial. EuroIntervention. 2021;17:466–73.

21. Grejs AM, Gjedsted J, Thygesen K, et al. The extent of myocardial injury during prolonged targeted temperature management after out-of-hospital cardiac arrest. Am J Med. 2017;130:57–46.

22. Chung JZ, Dallas Jones GR. Effect of renal function on serum cardiac troponin T – population and individual effects. Clin Biochem. 2015;48:807–10.

23. Chesney NC, Szymmer K, Bärány P, et al. Association between renal function and troponin T over time in stable chronic kidney disease patients. J Am Heart Assoc. 2019;8(21):e13091-13111.

24. Amor AP, Salisbury AC, McCullough PA, et al. Trends in the incidence of acute kidney injury in patients hospitalized with acute myocardial infarction. Arch Intern Med. 2012;172:246–53.

25. Yanta J, Guyette F, Doshi A, Callaway C, Rittenberger J. Renal dysfunction is common following resuscitation from out-of-hospital cardiac arrest. Resuscitation. 2013;84:1371–4.

26. Roman-Pognuz E, elmer J, et al. Markers of cardiogenic shock predict persistent acute kidney injury after out of hospital cardiac arrest. Heart Lung. 2019;48:126–30.

27. Zeiner A, Sunder-Plassmann G, Sterz F, et al. The effect of mild therapeutic hypothermia on renal function after cardiopulmonary resuscitation in men. Resuscitation. 2004;63:253–61.

28. DeRosa S, Cal MD, Ioannidis M, et al. The effect of whole-body cooling on renal function in post-cardiac arrest patients. BMC Nephrol. 2017;18:376–86.

29. Strand K, Særeide E, Kikegaard H, et al. The influence of prolonged temperature management on acute kidney injury after out-of-hospital cardiac arrest: a post hoc analysis of the TTH48 trial. Resuscitation. 2020;151:10–7.

30. Lemkes JS, Janssens GN, van der Hoeven NW, et al. Coronary angiography after cardiac arrest without ST-segment elevation. N Engl J Med. 2019;380:1397–407.

31. Rundgren M, Ullen S, Morgan MPG, et al. Renal function after out-of-hospital cardiac arrest; the influence of temperature management and coronary angiography, a post-hoc study of the target temperature management trial. Crit Care. 2019;23:163–73.

32. Wang AY, Lai KN. Use of cardiac biomarkers in end-stage renal disease. J Am Soc Nephrol. 2008;19:1643–52.

33. Newby UK, Jesse RL, Babb JD, et al. ACCF 2012 expert consensus document on practical clinical considerations in the interpretation of troponin elevations: a report of the American College of Cardiology Foundation task force on clinical expert consensus documents. J Am Coll Cardiol. 2012;60:2427–63.

34. Ellis K, Dreisbach AW, Lertora JL. Plasma elimination of cardiac troponin I in end-stage renal disease. South Med J. 2001;94:993–6.

35. Diris JH, Hackeng CM, Kooman JP, et al. Impaired renal clearance explains elevated troponin T fragments in hemodialysis patients. Circulation. 2004;109:23–5.

36. Ameloot K, Jakkula P, Hästbacka J, et al. Optimum blood pressure in patients with shock after acute myocardial infarction and cardiac arrest. J Am Coll Cardiol. 2020;76:812–24.

37. Gilje P, Koul S, Thomsen JH, Devaux Y, Friborg H, Kuiper M, Horn J, Nielsen N, Pellis T, Stammer P, Wise MP, Kjaergaard J, Hassager C, Erlinge D. High-sensitivity troponin-I as a prognostic marker after out-of-hospital cardiac arrest – A targeted temperature management (TTM) trial substudy. Resuscitation. 2016;107:156–61. https://doi.org/10.1016/j.resuscitation.2016.06.024.

38. Thygesen K, Mair J, Giannitsis E, et al. Study group on biomarkers in cardiology of the ESC/WGOACC. Recommendations for the use of cardiac troponin measurement in acute cardiac care. Eur Heart J. 2010;31:2197–204.

39. Thygesen K, Mair J, Giannitsis E, et al. Study group on biomarkers in cardiology of the ESC/WGOACC. How to use high-sensitivity cardiac troponins in acute cardiac care. Eur Heart J. 2012;33:2252–7.

40. Rainio P, Sormunen R, Lepojärvi M, Nissinen J, Kaukoranta P, Peuhkurinen K. Ultrastructural changes during continuous retrograde warm and mild hypothermic blood cardioplegia for coronary bypass operations. J Thorac Cardiovasc Surg. 1995;110:81–8.

41. Kurz K, Giannitsis E, Becker M, Hess G, Zdunek D, Katus HA. Comparison of the new high sensitive cardiac troponin T with myoglobin, h-FABP and cTnT for early identification of myocardial necrosis in the acute coronary syndrome. Clin Res Cardiol. 2011;3:209–15.

42. Chisholm GE, Grejs A, Thim T, et al. Safety of therapeutic hypothermia combined with primary percutaneous coronary intervention after out-of-hospital cardiac arrest. Eur J Heart Acute Cardiovasc Care. 2015;4:60–3.

43. Dankiewicz J, Cronberg T, Lilja G, et al. Hypothermia versus normothermia after out-of-hospital cardiac arrest. N Engl J Med. 2021;384:2283–94.

44. Kelly FE, Nolan JP. The effects of mild induced hypothermia on the myocardium: a systematic review. Anaesthesia. 2010;65:505–15.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.